Glenmark Pharmaceuticals Limited Stock Price Today (NSE: GLENMARK)
Fundamental Score
Glenmark Pharmaceuticals Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Glenmark Pharmaceuticals Limited share price today is ₹2410.00, up +1.61% on NSE/BSE as of 16 September 2026. Glenmark Pharmaceuticals Limited (GLENMARK) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹68.01K (Cr). The 52-week high for GLENMARK share price is ₹2537.60 and the 52-week low is ₹1792.60. At a P/E ratio of 37.83x, GLENMARK is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 0.00% and a debt-to-equity ratio of 0.00.
Glenmark Pharmaceuticals Limited Share Price Chart — NSE/BSE Historical Performance
Glenmark Pharmaceuticals Limited share price chart: 9.91% return over the past month. 52-week high ₹2537.60, 52-week low ₹1792.60.
Glenmark Pharmaceuticals Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹2371.70 | ₹2425.80 | ₹2306.30 | ₹2410.00 | 6.78L (Cr) | |
| ₹2420.80 | ₹2429.80 | ₹2346.60 | ₹2371.70 | 2.76L (Cr) | |
| ₹2411.20 | ₹2431.90 | ₹2384.10 | ₹2419.20 | 3.47L (Cr) | |
| ₹2445.90 | ₹2449.90 | ₹2403.10 | ₹2415.00 | 2.62L (Cr) | |
| ₹2486.90 | ₹2486.90 | ₹2400.10 | ₹2435.00 | 4.25L (Cr) | |
| ₹2469.90 | ₹2492.00 | ₹2439.00 | ₹2474.50 | 4.47L (Cr) | |
| ₹2420.20 | ₹2472.00 | ₹2420.20 | ₹2451.90 | 2.68L (Cr) | |
| ₹2454.50 | ₹2456.70 | ₹2422.70 | ₹2437.20 | 4.13L (Cr) | |
| ₹2470.00 | ₹2471.80 | ₹2425.10 | ₹2459.00 | 4.81L (Cr) | |
| ₹2455.00 | ₹2476.90 | ₹2420.00 | ₹2460.00 | 5.16L (Cr) |
Glenmark Pharmaceuticals Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹2480.00 | ₹2494.90 | ₹2306.30 | ₹2410.00 | -2.82% | |
| ₹2256.40 | ₹2537.60 | ₹2162.00 | ₹2480.00 | +9.91% | |
| ₹2196.40 | ₹2326.10 | ₹2142.80 | ₹2233.90 | +1.71% | |
| ₹2288.80 | ₹2300.00 | ₹2101.00 | ₹2204.30 | -3.69% | |
| ₹2406.30 | ₹2440.00 | ₹2226.30 | ₹2274.90 | -5.46% | |
| ₹2180.00 | ₹2474.00 | ₹1966.50 | ₹2406.30 | +10.38% | |
| ₹2112.50 | ₹2297.90 | ₹2031.10 | ₹2131.70 | +0.91% | |
| ₹1935.10 | ₹2159.80 | ₹1842.00 | ₹2136.70 | +10.42% | |
| ₹2034.00 | ₹2147.50 | ₹1910.10 | ₹2015.90 | -0.89% | |
| ₹1950.00 | ₹2082.50 | ₹1892.70 | ₹2035.20 | +4.37% | |
| ₹1889.10 | ₹1958.00 | ₹1801.40 | ₹1946.20 | +3.02% | |
| ₹1950.21 | ₹1990.00 | ₹1792.60 | ₹1891.20 | -3.03% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Glenmark Pharmaceuticals Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Glenmark Pharmaceuticals Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GLENMARK across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Excellent ROCE Performance (18.58%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (16.71%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (930.33%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (23.10%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Strong Profit Growth Track Record (25.68% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (10.51x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 1.56)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Institutional Confidence (FII+DII: 39.63%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Below-Average Return on Equity (0.00%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
High Price-to-Book Ratio (7.68x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Negative Free Cash Flow (₹-317.50 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Glenmark Pharmaceuticals Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Glenmark Pharmaceuticals Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Glenmark Pharmaceuticals LimitedGlenmark Pharma...Selected✓ GLENMARK • 532296 | 70.7/100 | ₹2410.00₹2410 | ₹68010.20₹68010.20 | 37.83Average 37.8 Average | 0.00%Poor 0.00% Poor | 18.58%Good 18.58% Good | 0.00Excellent 0.0 Excellent | 25.68%Excellent 25.68% Excellent | 9.19%Good 9.19% Good | 0.11% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9467.50₹9468 | ₹250888.75₹250888.75 | 85.90Average 85.9 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4939.50₹4940 | ₹167182.32₹167182.32 | 78.91Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1371.90₹1372 | ₹110828.94₹110828.94 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.10₹1941 | ₹104867.93₹104867.93 | 95.81Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1683.00₹1683 | ₹96839.82₹96839.82 | 26.30Average 26.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.70₹2101 | ₹96054.51₹96054.51 | 17.36Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1144.50₹1145 | ₹95565.75₹95565.75 | 29.58Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2293.70₹2294 | ₹94729.81₹94729.81 | 46.35Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price250888.75 Cr
- Torrent Pharmaceuticals Limited share price167182.32 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110828.94 Cr
Glenmark Pharmaceuticals Limited PE Ratio History
Historical price-to-earnings ratio for GLENMARK — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹37.11 | ₹2035.20 | 54.8x |
| FY 2023 | ₹10.53 | ₹852.00 | 80.9x |
| FY 2022 | ₹33.37 | ₹424.80 | 12.7x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Glenmark Pharmaceuticals Limited Dividend History
Annual cash dividends paid by GLENMARK — dividend yield 0.11%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹70.44 Cr |
| FY 2024 | ₹117.75 Cr |
| FY 2023 | ₹136.61 Cr |
| FY 2022 | ₹92.69 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Glenmark Pharmaceuticals Limited Quarterly Performance
Latest quarterly metrics for GLENMARK — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
23.10%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
930.33%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
9.19%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
25.68%
Compounded annual net profit growth over 5 years
Glenmark Pharmaceuticals Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for GLENMARK — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Glenmark Pharmaceuticals Limited Financial Statements
Annual income statement, balance sheet and cash flow for Glenmark Pharmaceuticals Limited (GLENMARK) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Glenmark Pharmaceuticals Limited
About GLENMARK (Glenmark Pharmaceuticals Limited)
Glenmark Pharmaceuticals Ltd is a dynamic global pharmaceutical company driven by innovation and a commitment to improving healthcare outcomes. With a robust presence across both e...merging and developed markets, Glenmark operates at the forefront of pharmaceutical research, development, and manufacturing. The company is actively engaged in pioneering new chemical entities and biosimilars, strategically focusing on therapeutic areas with significant unmet medical needs. Glenmark distinguishes itself through its agile approach to drug development, leveraging cutting-edge technologies and a deep understanding of global healthcare challenges to deliver impactful solutions for patients worldwide. Glenmark's diverse portfolio encompasses a wide range of pharmaceutical products, including specialty medicines, generics, and over-the-counter treatments. This comprehensive offering allows Glenmark to address various healthcare needs across multiple therapeutic areas. The company demonstrates considerable strength in dermatology, respiratory, and oncology, with a growing focus on immunology and other specialized segments. By combining scientific expertise with commercial acumen, Glenmark successfully navigates the complexities of the pharmaceutical industry, ensuring its products reach patients in need while upholding the highest standards of quality and safety. With a global footprint that spans numerous countries, Glenmark Pharmaceuticals maintains a robust infrastructure to support its research, manufacturing, and commercial operations. The company's state-of-the-art manufacturing facilities adhere to stringent international regulatory standards, ensuring the consistent quality and reliability of its products. Glenmark actively fosters strategic collaborations and partnerships to accelerate its research and development efforts and expand its market reach. Driven by a dedication to innovation, quality, and patient well-being, Glenmark Pharmaceuticals continues to make significant contributions to the global healthcare landscape.
Company Details
Key Leadership
GLENMARK Share Price: Frequently Asked Questions
What is the current share price of Glenmark Pharmaceuticals Limited?
Glenmark Pharmaceuticals Limited (GLENMARK) trades at ₹2410.00 on NSE and BSE. Market cap ₹68.01K (Cr). Educational data only.
What is the P/E ratio of Glenmark Pharmaceuticals Limited?
Glenmark Pharmaceuticals Limited has a P/E of 37.83x vs industry average 34.89x.
What is the Bull Run score for Glenmark Pharmaceuticals Limited?
Glenmark Pharmaceuticals Limited has a Bull Run score of 70.7/100 based on 25+ financial parameters.
Does Glenmark Pharmaceuticals Limited pay dividends?
Glenmark Pharmaceuticals Limited has a dividend yield of 0.11%. Past dividends don't guarantee future payments.
What is the ROE of Glenmark Pharmaceuticals Limited?
Glenmark Pharmaceuticals Limited has ROE of 0.00%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Glenmark Pharmaceuticals Limited?
Glenmark Pharmaceuticals Limited has debt-to-equity of 0.00.
Is Glenmark Pharmaceuticals Limited a good investment?
Bull Run gives Glenmark Pharmaceuticals Limited a score of 70.7/100. This is not investment advice — consult a SEBI-registered advisor.